| Primary |
| Product Used For Unknown Indication |
35.0% |
| Drug Use For Unknown Indication |
21.8% |
| Macular Degeneration |
19.7% |
| Age-related Macular Degeneration |
14.2% |
| Choroidal Neovascularisation |
1.7% |
| Diabetic Retinal Oedema |
1.6% |
| Maculopathy |
1.5% |
| Hypertension |
0.9% |
| Retinal Vein Occlusion |
0.8% |
| Diabetic Retinopathy |
0.7% |
| Macular Oedema |
0.4% |
| Diabetes Mellitus |
0.4% |
| Visual Impairment |
0.2% |
| Visual Acuity Reduced |
0.2% |
| Atrial Fibrillation |
0.2% |
| Off Label Use |
0.2% |
| Polypoidal Choroidal Vasculopathy |
0.1% |
| Eye Haemorrhage |
0.1% |
| Glaucoma |
0.1% |
| Myopia |
0.1% |
|
| Death |
35.1% |
| Visual Acuity Reduced |
14.4% |
| Cerebrovascular Accident |
10.9% |
| Myocardial Infarction |
5.9% |
| Visual Impairment |
3.5% |
| Eye Haemorrhage |
3.5% |
| Retinal Haemorrhage |
2.9% |
| Malaise |
2.8% |
| Retinal Pigment Epithelial Tear |
2.6% |
| Transient Ischaemic Attack |
2.6% |
| Vitreous Haemorrhage |
2.2% |
| Vision Blurred |
1.9% |
| Pneumonia |
1.7% |
| Drug Ineffective |
1.7% |
| Fall |
1.6% |
| Vitreous Floaters |
1.5% |
| Eye Pain |
1.3% |
| Hypertension |
1.3% |
| Blindness |
1.3% |
| Cerebral Infarction |
1.3% |
|
| Secondary |
| Product Used For Unknown Indication |
31.8% |
| Macular Degeneration |
19.9% |
| Drug Use For Unknown Indication |
17.8% |
| Age-related Macular Degeneration |
16.9% |
| Choroidal Neovascularisation |
3.0% |
| Diabetic Retinal Oedema |
2.0% |
| Maculopathy |
1.5% |
| Diabetic Retinopathy |
1.2% |
| Hypertension |
1.2% |
| Macular Oedema |
1.1% |
| Retinal Vein Occlusion |
1.0% |
| Diabetes Mellitus |
0.5% |
| Off Label Use |
0.4% |
| Retinal Haemorrhage |
0.4% |
| Detachment Of Retinal Pigment Epithelium |
0.3% |
| Glaucoma |
0.2% |
| Myopia |
0.2% |
| Pain |
0.2% |
| Cystoid Macular Oedema |
0.2% |
| Retinal Neovascularisation |
0.2% |
|
| Visual Acuity Reduced |
23.2% |
| Myocardial Infarction |
10.2% |
| Cerebrovascular Accident |
10.0% |
| Death |
7.2% |
| Retinal Pigment Epithelial Tear |
4.9% |
| Retinal Haemorrhage |
4.8% |
| Visual Impairment |
4.2% |
| Vitreous Haemorrhage |
3.9% |
| Cataract |
3.4% |
| Transient Ischaemic Attack |
3.2% |
| Vision Blurred |
3.1% |
| Malaise |
3.0% |
| Vitreous Floaters |
2.9% |
| Intraocular Pressure Increased |
2.7% |
| Age-related Macular Degeneration |
2.6% |
| Drug Ineffective |
2.5% |
| Inappropriate Schedule Of Drug Administration |
2.4% |
| Cerebral Infarction |
2.1% |
| Acute Myocardial Infarction |
1.8% |
| Eye Haemorrhage |
1.8% |
|
| Concomitant |
| Drug Use For Unknown Indication |
22.1% |
| Product Used For Unknown Indication |
21.7% |
| Macular Degeneration |
17.1% |
| Hypertension |
5.4% |
| Osteoporosis |
3.9% |
| Muscle Spasms |
3.1% |
| Toothache |
3.1% |
| Age-related Macular Degeneration |
2.7% |
| Chronic Obstructive Pulmonary Disease |
2.7% |
| Bone Neoplasm Malignant |
2.3% |
| Osteoporosis Postmenopausal |
2.3% |
| Arthritis |
1.6% |
| Atrial Fibrillation |
1.6% |
| Barrett's Oesophagus |
1.6% |
| Blood Pressure |
1.6% |
| Depression |
1.6% |
| Groin Pain |
1.6% |
| Prophylaxis |
1.6% |
| Pseudomonas Infection |
1.6% |
| Breast Cancer Metastatic |
1.2% |
|
| Visual Impairment |
14.8% |
| Weight Decreased |
14.8% |
| Visual Acuity Reduced |
9.8% |
| Macular Degeneration |
6.6% |
| Malaise |
4.9% |
| Age-related Macular Degeneration |
3.3% |
| Arthralgia |
3.3% |
| Blindness Unilateral |
3.3% |
| Breast Cancer |
3.3% |
| Death |
3.3% |
| Drug Ineffective |
3.3% |
| Endodontic Procedure |
3.3% |
| Eye Oedema |
3.3% |
| Fatigue |
3.3% |
| Lacrimation Increased |
3.3% |
| Multi-organ Failure |
3.3% |
| Muscle Spasms |
3.3% |
| Nausea |
3.3% |
| Nephrogenic Systemic Fibrosis |
3.3% |
| Ocular Hyperaemia |
3.3% |
|
| Interacting |
| Macular Degeneration |
26.9% |
| Age-related Macular Degeneration |
23.1% |
| Lipids Increased |
23.1% |
| Hiccups |
11.5% |
| Chemotherapy |
7.7% |
| Off Label Use |
3.8% |
| Product Used For Unknown Indication |
3.8% |
|
| Visual Acuity Reduced |
50.0% |
| Pancreatic Carcinoma |
33.3% |
| Drug Interaction |
8.3% |
| Second Primary Malignancy |
8.3% |
|
